92 related articles for article (PubMed ID: 10728699)
1. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis.
Schorge JO; Muto MG; Lee SJ; Huang LW; Welch WR; Bell DA; Keung EZ; Berkowitz RS; Mok SC
Cancer Res; 2000 Mar; 60(5):1361-4. PubMed ID: 10728699
[TBL] [Abstract][Full Text] [Related]
2. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum.
Bandera CA; Muto MG; Welch WR; Berkowitz RS; Mok SC
Oncogene; 1998 Jul; 16(26):3455-9. PubMed ID: 9692553
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
4. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
Schorge JO; Muto MG; Welch WR; Bandera CA; Rubin SC; Bell DA; Berkowitz RS; Mok SC
J Natl Cancer Inst; 1998 Jun; 90(11):841-5. PubMed ID: 9625172
[TBL] [Abstract][Full Text] [Related]
5. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum.
Huang LW; Garrett AP; Schorge JO; Muto MG; Bell DA; Welch WR; Berkowitz RS; Mok SC
Am J Clin Pathol; 2000 Jul; 114(1):93-9. PubMed ID: 10884804
[TBL] [Abstract][Full Text] [Related]
6. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
7. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma.
Altaras MM; Bernheim J; Zehavi T; Drucker L; Uziel O; Fishman A
Gynecol Oncol; 2002 Feb; 84(2):245-51. PubMed ID: 11812082
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum.
Muto MG; Welch WR; Mok SC; Bandera CA; Fishbaugh PM; Tsao SW; Lau CC; Goodman HM; Knapp RC; Berkowitz RS
Cancer Res; 1995 Feb; 55(3):490-2. PubMed ID: 7834614
[TBL] [Abstract][Full Text] [Related]
10. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
11. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
13. Allelotype of papillary serous peritoneal carcinomas.
Cass I; Baldwin RL; Fasylova E; Fields AL; Klinger HP; Runowicz CD; Karlan BY
Gynecol Oncol; 2001 Jul; 82(1):69-76. PubMed ID: 11426964
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Papillary serous carcinoma of the peritoneum: analysis of clonality of peritoneal tumors.
Nishimura- M; Wakabayashi M; Hashimoto T; Shibata J; Ueyama H; Ebina M; Fujiyama Y; Bamba T
J Gastroenterol; 2000; 35(7):540-7. PubMed ID: 10905363
[TBL] [Abstract][Full Text] [Related]
16. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
17. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
19. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
20. Low expression of bcl-2 in Brca1-associated breast cancers.
Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
